Social cognition deficits and psychopathic traits in young people seeking mental health treatment

PLoS One. 2013 Jul 4;8(7):e67753. doi: 10.1371/journal.pone.0067753. Print 2013.

Abstract

Antisocial behaviours and psychopathic traits place an individual at risk for criminality, mental illness, substance dependence, and psychosocial dysfunction. Social cognition deficits appear to be associated with psychopathic traits and are believed to contribute to interpersonal dysfunction. Most research investigating the relationship of these traits with social cognition has been conducted either in children or adult forensic settings. We investigated whether psychopathic traits were associated with social cognition in 91 young people presenting for mental healthcare (aged between 15 and 25 years). Participants completed symptom severity measures, neuropsychological tests, the Reading the Mind in the Eyes Test of social cognition (RMET), and the Antisocial Process Screening Device (APSD) to assess psychopathic personality traits. Correlation analyses showed poorer social cognition was associated with greater psychopathic traits (r = -.36, p = .01). Interestingly, social cognition performance predicted unique variance in concurrent psychopathic personality traits above gender, IQ sustained attention, and working memory performance. These findings suggest that social cognitive impairments are associated with psychopathic tendencies in young people presenting for community mental healthcare. Research is needed to establish the directionality of this relationship and to determine whether social cognition training is an effective treatment amongst young people with psychopathic tendencies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antisocial Personality Disorder / physiopathology*
  • Antisocial Personality Disorder / psychology
  • Attention
  • Cognition*
  • Community Health Services
  • Female
  • Humans
  • Male
  • Mental Health
  • Models, Neurological
  • Neuropsychological Tests

Grants and funding

AJG, DFH, and IBH were supported by an NHMRC Australia Fellowship awarded to IBH (No. 464914). DFH was supported by a grant from the NSW Ministry of Health, Mental Health and Drug & Alcohol Office. SLN was funded by an NHMRC Clinical Research Fellowship (No. 402864). This research was further supported by an NHMRC Program Grant (No. 350241), an ARC linkage Grant (LP110100513) and a Centres of Clinical Research Excellence Grant (No. 264611). EMS and IBH have received educational and research programs/grants that are supported by the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, and Eli Lilly). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.